TransMedics Group, Inc. (NASDAQ:TMDX) Short Interest Update

TransMedics Group, Inc. (NASDAQ:TMDX) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 11,130,000 shares, a growth of 23.8% from the January 15th total of 8,990,000 shares. Based on an average daily volume of 2,000,000 shares, the days-to-cover ratio is currently 5.6 days.

Insider Activity

In other news, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Clear Creek Financial Management LLC purchased a new position in TransMedics Group during the 4th quarter worth $352,000. Vaughan Nelson Investment Management L.P. boosted its holdings in shares of TransMedics Group by 9.9% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock valued at $22,547,000 after acquiring an additional 32,605 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of TransMedics Group in the third quarter valued at about $2,560,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of TransMedics Group by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after acquiring an additional 6,634 shares in the last quarter. Finally, Zacks Investment Management purchased a new stake in shares of TransMedics Group in the third quarter valued at about $1,607,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Stock Performance

TransMedics Group stock traded up $0.96 during midday trading on Friday, hitting $72.18. 1,013,799 shares of the company’s stock were exchanged, compared to its average volume of 2,287,730. TransMedics Group has a 12-month low of $55.00 and a 12-month high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a market cap of $2.42 billion, a price-to-earnings ratio of 76.79 and a beta of 2.12. The firm’s 50 day simple moving average is $65.79 and its 200 day simple moving average is $107.46.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on TMDX. Robert W. Baird reduced their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Canaccord Genuity Group dropped their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Finally, TD Cowen dropped their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.